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Signals that elevate intracellular levels of cyclic adenosine monophosphate (cAMP) are among the factors that control lipopolysaccharide
(LPS)-mediated inflammatory mediator production by macrophages. cAMP signaling is also involved in maintaining body functions that are
commonly impaired in sepsis, including the endothelial cell barrier function and heart function. Several agents successfully used for sepsis
intervention target cAMP signaling, and it was recently shown that liver and lung may be protected from inflammation injury by cAMP-elevating
phosphodiesterase inhibitors. Here, we show that LPS attenuates adenylyl cyclase (AC) mRNA levels in liver, lung, heart, spleen and kidney in an
animal model of endotoxemia, and in macrophages from liver and lung. In particular, AC5, AC6, AC7 and AC9 mRNA were reduced in most
tissues examined and in tissue macrophages. In Kupffer cells, prostaglandin E2-mediated cAMP production was inhibited by LPS treatment. The
reduction in AC mRNA by LPS would be expected to lead to a lowered potential for cAMP production in most organs, and in particular, changes
in AC6 mRNA may affect endothelial cell barrier function and heart function. In contrast, AC4 mRNAwas elevated in heart and lung. The present
work indicates a possible mechanism for LPS-mediated alteration of cAMP signaling in vivo.
© 2006 Elsevier B.V. All rights reserved.Keywords: Adenylyl cyclase; cAMP; Lipopolysaccharide; Endotoxemia; Inflammation1. Introduction
Despite several advances in treatment during recent years,
sepsis continues to be a major cause of morbidity in Intensive
Care Units [1]. Sepsis is the body's systemic inflammatory
response to infection, initiated when pathogens or their
components such as lipopolysaccharide (LPS) trigger cells of
the innate immune system. Notably, LPS can alone instigate
many of the pathophysiological events that occur within the
host during a septic episode [2].
Among the most important clinical signs of sepsis are arterial
hypotension, acute oliguria and reduced tissue perfusion,
usually followed and complicated by organ dysfunction [3].Abbreviations: AC, adenylyl cyclase; cAMP, cyclic adenosine monopho-
sphate; IL, interleukin; LPS, lipopolysaccharide; RT-PCR, reverse transcriptase-
polymerase chain reaction; TNF, tumor necrosis factor
⁎ Corresponding author. Tel.: +47 23073520; fax: +47 23073530.
E-mail address: m.k.dahle@medisin.uio.no (M.K. Dahle).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.08.007Many of the physiological functions disturbed during sepsis are
under control by the second messenger cyclic adenosine
monophosphate (cAMP) signaling pathway. cAMP is derived
from adenosine triphosphate (ATP) by one of at least ten
currently identified isoforms of the adenylyl cyclase (AC)
enzymes (AC 1–9 and soluble AC), which differ in cell-specific
expression, regulation and effects, providing an intracellular
system suited for finely targeted signaling. A number of ligands
that stimulate AC activity and elevate cAMP levels have been
demonstrated to confer beneficial effects in sepsis and is
currently used for sepsis intervention. These include the
vasopressors norepinephrine, epinephrine, dopamine and vaso-
pressin that account for haemodynamic and renal support [4,5],
and adrenomedullin that may improve tissue perfusion, organ
function and protect against endothelial apoptosis [6]. Treat-
ment with a non-specific inhibitor of cAMP degradation by
phosphodiesterases (Pentoxifyllin) in a rat endotoxemia model
attenuated pro-inflammatory cytokine release and reduced liver
injury [7], and recently, pentoxifyllin was also demonstrated to
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same model [8]. In addition, mice deficient in the cAMP-
inducing adenosine 2A (A2A) receptors and pituitary adenylyl
cyclase activating polypeptide (PACAP) receptors were shown
to be more susceptible to developing sepsis, and the liver was
pointed out as the organ mainly affected by these receptor
deficiencies [9,10].
Macrophages play a key role in modulating the host immune
response, as producers of a wide range of pro-inflammatory and
anti-inflammatory mediators. Kupffer cells (resident liver
macrophages) account for more than 50% of resident macro-
phages in the body [11], and are a primary source of
inflammatory mediators [12,13]. Similarly, alveolar macro-
phages are numerous and responsible for inducing the
inflammatory response in lung [14]. The cAMP signal in
macrophages functions primarily by reducing the endotoxin-
mediated production of pro-inflammatory mediators including
tumor necrosis factor alpha (TNFα), interleukin (IL)-8, IL-12,
IL-18 and inducible NO synthase (iNOS) [15–18], and cAMP
signaling is also reported to enhance LPS-mediated production
of anti-inflammatory IL-10 [19–21]. Inhibition of the pro-
inflammatory response may protect against the onset of sepsis,
but it should be noted that immunosuppression may be an
unfavorable side-effect.
Impaired production of cAMP in peripheral blood mono-
cytes has been demonstrated in patients with severe sepsis [22]
and in monocytes from healthy donors exposed to septic serum
[23], suggesting that adenylyl cyclase activity may be lowered
in sepsis. Despite many indications that reduced adenylyl
cyclase activity play a role in the pathophysiology of sepsis, the
expression and regulation of specific adenylyl cyclase isoforms
have so far been scarcely studied. We aimed to investigate the
effects of LPS on the gene expression of adenylyl cyclase
isoforms in organs using a rat model of endotoxemia, and in
primary tissue macrophages in culture.
2. Experimental procedures
2.1. In vivo experiments
This study was carried out on adult male Wistar rats (230 to 280 g Institute
of National Health, Oslo, Norway) receiving a standard diet and water ad
libitum. The investigation was approved by the national ethics committee for
animal experiments. Animals were anesthetized with thiopentone sodium
(120 mg/kg, i.p., Intraval Sodium), and anesthesia was maintained by
supplementary injections of thiopentone sodium as required. A tracheostomy
was performed to facilitate respiration, and rectal temperature was maintained
at 37 °C using a homeothermic blanket. The right carotid artery was connected
to a pressure transducer for hemodynamic monitoring. The jugular vein was
cannulated for the administration of bacterial lipopolysaccharide or vehicle
(0.9% sodium chloride (NaCl)). The bladder was also cannulated to facilitate
urine flow. Blood pressure was allowed to stabilize for 10–15 min, followed by
injection of 0.9%NaCl or LPS (6mg/kg, Sigma, St. Lewis, USA) into the jugular
vein for a 10-min period. After 6 h the animalswere exanguinated, and samples of
liver, lung, heart, kidney and spleen were rapidly frozen in liquid nitrogen.
2.2. Isolation of Kupffer cells
Kupffer cells were isolated from rat liver (adult male Sprague–Dawley rats
300–500 gram, Institute of National Health) as previously described [15]. Inbrief, Kupffer cell isolation was based on digestion of the liver by collagenase P
(0.24 mg/ml, Roche, Mannheim, Germany), gradient centrifugation in Percoll
(Pharmacia Fine Chemicals, Uppsala, Sweden), and selective adherence.
Kupffer cells were cultured in 6-well plates (3×106 cells/plate) for 48 h in
RPMI 1640 (BioWhittaker Europe, Verviers, Belgium) in the presence of 10%
fetal calf serum (GIBCO, Grand Island, NY), L-glutamine (2 mM, GIBCO) and
antibiotics (penicillin and streptomycin, GIBCO) prior to experiments. Purity of
Kupffer cells were assessed by mouse anti-rat ED-2 IgG antibody (Serotec,
Oxford, UK), demonstrating >95% Kupffer cells in the culture.
2.3. Isolation of alveolar macrophages
Pulmonary alveolar macrophages were collected from the bronchopulmo-
nary lavage fluid of rats (adult male Sprague–Dawley rats 300–500 gram,
Institute of National Health), using a modified procedure by Leeper-Woodford
[24]. Animals were anesthetized and exsanguinated, followed by lavage of the
lungs with 2×20 ml phosphate-buffered saline (Sigma) with heparin (10 U/l).
The lavage fluid was centrifuged (2500×g for 10 min), after which the pellet was
resuspended in RPMI 1640 (BioWhittaker Europe) in the presence of 10% fetal
bovine serum (GIBCO) and antibiotics (penicillin and streptomycin, GIBCO).
Cells were plated in 6-well culture dishes and incubated for 2 h (37 °C and 5%
CO2), followed by removal of non-adherent cells. Alveolar cells were then
cultured for 24 h prior to experiments. Monoclonal mouse anti-rat CD68 IgG
(Serotec) was used to assess the homogeneity of macrophages aspirated by
bronchoalveolar lavage. The culture proved to be >95% pure.
2.4. Cell culture experiments
Kupffer cells and alveolar macrophages were incubated in the presence or
absence of LPS (1 μg/ml) for 6 h prior to preparation of RNA. In experiments
for cAMP assay, cells were treated for 15 min by forskolin (Calbiochem, San
Diego, CA) or prostaglandin E2 (PGE2, Calbiochem) or the reagent diluent
dimethylsulfoxide (DMSO, Sigma).
2.5. Isolation of RNA
For Kupffer cell or alveolar macrophage RNA preparation, cultures in 6-well
plates were scraped and suspended in RNeasy lysis buffer (Qiagen, Hilding,
Germany). Total RNA from whole liver, lung, spleen and kidney were obtained
by grinding tissue samples in a pre-cooled mortar, and 30 mg of frozen material
was homogenized by ultra Turrax (20,000/min) in RNeasy lysis buffer (Qiagen).
The RNAwas further isolated using RNeasy mini kit (Qiagen), according to the
manufacturer's protocol.
2.6. Real-time Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR)
Relative levels of adenylyl cyclase mRNAwas analyzed by RT-PCR, using
the ABI Prism 7900HT (Applied Biosystems, Foster City, CA) with sequence-
specific primers and probes (Table 1). In brief, 100 ng of total RNAwas reverse
transcribed using Taqman Reverse Transcription Reagents (Applied Biosys-
tems) and real-time PCR was performed with 2× qPCR Master Mix for SYBR
Green (Eurogentec, Liege, Belgium), 300 nM sense and anti-sense primers,
cDNA and water made up to 25 μL. The specificities of all SYBR Green assays
were confirmed by melting point analysis. The concentration of 18S mRNAwas
used for normalization of target gene expression (18S Pre-developed Assay
Reagents, Applied Biosystems), and results were confirmed using a second
reference gene (β-actin). Standard curves with at least five points were run at the
RT-level for each tissue analyzed. All RNA samples were DNase treated, and all
primer sets include intron-spanning primers. As an additional control of DNA
contamination, all standard curve samples were tested by replacing the RT
enzyme with RNase-free water. No PCR products were detected in these
controls. All samples were run in triplicate, standard curves were run on the
same plate and the standard curve method was used to calculate the relative gene
expression. For representative gel images, 20 μl of PCR samples were run on a
2% agarose gel containing ethidium bromide along with a 100 bp DNA ladder
(Invitrogen), and bands were visualized in UV light.
Table 1
Primers used in the real-time PCR assays
mRNA Primer sequence Amplicon location Length (bp)
AC1 Fwd: 5′-CTG CTC TCG TGA CTG AGG AAG-3′ Exons 21–22 192
Rev: 5′-CGC CTC TCC CAT AAG GAA AC-3′
AC2 Fwd: 5′-GGG AAG ATT AGT ACC ACG GAT-3′ Exons 15–19 293
Rev: 5′-AGG AGA AGC CAA GGATGG ACG-3′
AC3 Fwd: 5′-ATG AGC ACG AAC TGA ACC AGC T-3′ Exons 10–14 445
Rev: 5′-GTC CCA TGT AGT ACT GGA GAC AGC TC-3′
AC4 Fwd: 5′-AGC CAG CCT ACC CAG GTT-3′ Exons 1–3 283/89
Rev: 5′-GCT TGG GTC TGA GGT CA-3′
AC5 Fwd: 5′- GAG AAG AAG TAC TCC AAG CAG GTG-3′ Exons 10–15 167
Rev: 5′-AAC ACC ACC AAG GCC AGT AG-3′
AC6 Fwd: 5′-TCC TCG TAT TCC CAC ACT CC-3′ Exons 12–15 250
Rev: 5′-GTC CTC AGT GGG GTG TGA CT-3′
AC7 Fwd: 5′-ACG AGC TGC TGC TGA AGC-3′ Exons 24–27 198
Rev: 5′-AGT GCC TGT TGATTC CAT CC-3′
AC8 Fwd: 5′-CAG TCT GGG CCT GAG GAA ATT-3′ Exons 12–14 209
Rev: 5′-AAG TCA GGT TCT TCA AGG GTA-3′
AC9 Fwd: 5′-ACC TAC CTT TAC CCA AAG TGC ACG GAC AAT-3′ Exon 12 359
Rev: 5′-CTC GGC GCT GCC TCA CAC ACT CTT TGA GAC-3′
sAC Fwd: 5′-CGA GAA CAT CAG CAT CAC AGA-3′ Exons 23–24 231
Rev: 3′-CC AGG ATG AGATAG GCA GA-3′
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cAMP levels were measured by a competitive enzyme immunoassay (EIA,
Cayman Chemical Company, Ann Arbor, MI). Analyses were done in
accordance with the manufacturers' instructions.
2.8. Statistical analyses
Data were analysed by GraphPad Prism 4 (GraphPad Software, San Diego,
USA), using an unpaired t-test with equal variances assumed for tissue samples
and a paired t-test with equal variances assumed for cell cultures. Differences
with P<0.05 were considered significant.3. Results
The basal expression of adenylyl cyclase mRNA found in
various organ samples from sham-operated animals and from
lung and liver macrophages is summarized in Table 2. Note that
relative expression levels can only be compared between tissuesTable 2
Summary of isoform expression (based on values for cycle threshold)
Isoform Liver Lung Kidney Spleen Heart Kupffer Lung MΦ
AC1 + nd nd + + nd nd
AC2 nd + nd nd nd nd nd
AC3 nd nd nd nd nd nd nd
AC4 nd ++ nd ++ + +++ +
AC5 ++ ++++ ++ +++ ++++ +++ +
AC6 ++ ++++ ++ ++++ ++ ++ +
AC7 + +++ + ++++ + ++++ ++++
AC8 nd nd nd nd nd nd nd
AC9 + ++ + + nd + +
sAC nd nd nd nd nd + +
Based on mean relative expression from 4 to 8 animals. Intervals for cycle
threshold values based on cDNA from 2 ng total RNA; nd/not detected [>36], +
[35–32,5]. ++ [32,5–30], +++ [30–27,5], ++++ [27,5>]. Please note that values
are not comparable across different primer sets for quantification.for each single isoform due to differences in primer affinities.
As seen in the table, mRNA for AC4, AC5, AC6, AC7, AC9
and soluble (s)AC were observed in Kupffer cells and alveolar
macrophages. A representative gel image of PCR products
produced in Kupffer cells is shown in Fig. 1. All primer pairs
produce one DNA product corresponding to the expected
amplicon length. Primers for AC4 produce a band
corresponding to a splice variant that do not contain exon 2.
Intravenous injection of LPS to rats caused marked
regulation of adenylyl cyclase mRNA levels in different organs.
Notably, in the liver AC5, AC7 and AC9 mRNA were all
significantly attenuated by LPS treatment (Fig. 2A). In the lung,
AC4 mRNAwas increased 4-fold compared with sham operated
animals, whereas AC5, AC6 and AC7 mRNA levels were not
significantly altered by LPS treatment (Fig. 2B). Lung AC9
mRNA was reduced with a P-value of 0.061. Heart samples
showed no obvious regulation of AC5 or AC7, but a highly
significant 75% reduction of AC6 expression and once again an
increase in AC4 mRNA levels (Fig. 2C). Infusion of LPS
caused significant attenuation of AC5, AC6, AC7 and AC9
mRNA in whole kidney (Fig. 2D), following roughly the same
regulatory pattern as in whole liver. The most striking changes
were seen in spleen, where AC4, AC6, AC7 and AC9 mRNA
appeared to be reduced by 75–90% of the levels in
corresponding sham samples (Fig. 2E).Fig. 1. PCR products obtained in Kupffer cell extracts using primers for adenylyl
cyclases. 20 μl of PCR products obtained from the real-time RT-PCR reaction
were run on a 2% agarose gel. L: 100 bp DNA ladder.
Fig. 2. Expression of AC4, AC5, AC6, AC7 and AC9 mRNA in rat tissue after 6 h of endotoxemia. Total RNA was assessed by real-time RT-PCR using isoform-
specific primers, and normalized for 18S ribosomal RNA. Mean±SEM values are shown. The mean Sham mRNA expression of each isoform is set to 100. Each group
consists of 4–8 animals. P-values using an unpaired t-test with equal variances assumed for each isoform; (A) Liver AC5 0.004, AC6 0.11, AC7 0.028, AC9
0.005.(B) Lung AC4 0.012, AC5 0.78, AC6 0.38, AC7 0.46, AC9 0.061. (C) Heart AC4 0.085, AC5 0.574, AC6<0.001, AC7 0.641. (D) Kidney AC5<0.001,
AC6 0.048, AC7 0.031, AC9 0.003. (E) Spleen AC4 0.082, AC5 0.98, AC6 0.022, AC7 0.062, AC9 0.008.
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Fig. 3. Expression of AC4, AC5, AC6, AC7, AC9 and sAC mRNA in primary macrophages after 6 h of LPS treatment. Total RNAwas assessed by real-time RT-PCR
using isoform-specific primers, and normalized for 18S ribosomal RNA. Mean±SEM values are shown. The mean Sham mRNA expression of each isoform is set to
100. Each group consists of cells from 4 animals. P-values using an unpaired t-test with equal variances assumed for each isoform: (A) Alveolar macrophages AC4
0.44, AC5 0.031, AC6 0.24, AC7 0.13, AC9 0.58, sAC 0.084. (B) Kupffer cells AC4 0.003, AC5 0.56, AC6 0.94, AC7 0.022, AC9 0.037, sAC 0.17.
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cyclase mRNA expression in macrophages, rat Kupffer and
alveolar macrophage primary cell cultures were either stimu-
lated with LPS (1 μg/ml) or left untreated. Alveolar macro-
phages and Kupffer cells seemed to have lower basal expression
of AC5 and AC6 compared to whole lung and liver, but higher
levels of AC7 and AC9 mRNA. AC4 mRNAwas unaltered by
LPS in lung, whereas AC5, AC6, AC7, AC9 and soluble AC all
appeared to be reduced by 20 to 50% (Fig. 3A). In Kupffer cells
from liver we observed significant reduction of AC4, AC7 and
AC9 (Fig. 3B). We found expression of soluble AC (sAC) in
both alveolar macrophages and Kupffer cells, which weFig. 4. Intracellular levels of cAMP in Kupffer cells. Cells from two animals in
parallel samples were treated with LPS for 6 h (filled bars) or left untreated (open
bars) followed by treatment with cAMP-elevating agents (1 μM forskolin or
1 μM PGE2) or DMSO for 15 min. P-values using an unpaired t-test for LPS
pretreated vs. untreated cells: DMSO 0.297, Forskolin 1.132, PGE2 0.006.detected neither in whole lung nor whole liver. The expression
of sAC was not significantly altered by LPS treatment.
To clarify if changes found in adenylyl cyclase mRNA
production affected Kupffer cell cAMP production we analyzed
cAMP levels in Kupffer cells pretreated by LPS (1 μg/ml) for
6 h followed by 15 min of adenylyl cyclase activation by
forskolin (1 μM) or PGE2 (1 μM). As shown in Fig. 4, we found
that LPS treatment significantly inhibited cAMP production
induced by PGE2, but led to no changes in forskolin-mediated
cAMP-production. There was a non-significant tendency
towards elevated levels of cAMP in the absence of adenylyl
cyclase activator in LPS-treated cells.
4. Discussion
The main finding of the present study is a marked
reduction in the mRNA levels of most adenylyl cyclase
isoforms, both in vivo and in primary macrophages in culture
following LPS treatment. The only exception is the elevated
AC4 mRNA in heart and lung. We also characterized, for the
first time, the adenylyl cyclase isoform mRNA levels in two
of the largest resident macrophage populations, observing
higher amounts of AC7, AC9 and sAC mRNA compared to
samples from surrounding tissue.
Basal mRNA levels were examined in all tissue samples
from sham animals. Defer et al. have previously summarized
studies characterizing adenylyl cyclase mRNA levels in liver,
lung, heart and kidney [25], and our study show roughly the
same relative expression levels of AC isoform mRNA. An
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heart. Premont et al. [26] detected AC9 mRNA but not AC9
protein in heart when using a C-terminal antibody. However,
Hacker et al. [27] reported high levels of AC9 protein in heart
using an internal antibody. This could indicate that the AC9
expressed in heart is truncated. We have used primer pairs
located in the last exon of rat AC9 (exon 12), which would not
allow us to detect truncated versions of AC9 mRNA. It should
be noted that we examined tissue samples that were not
perfused, and the impact of mRNA originated from blood cells
will be determined by the extent of organ vascularization. For
the isoforms that exhibit several splice variants (AC7, AC8,
sAC) [26,28], our primers were designed to detect regions
common for all known variants. AC8 was only detected in lung
samples in our study, despite previous findings in macrophages
by others [29], and only a weak signal was detected in rat brain
tissue when used as a positive control (data not shown). Another
set of AC8 primers was tested, with equally negative results,
and our study does for that reason not include regulatory data
for AC8. Immunodetection of adenylyl cyclase proteins is
difficult due to low levels in most cells (0.01–0.001% of
membrane protein) [30], and the lack of high quality antibodies,
limiting our study to mRNA data.
Studies performed with phosphodiesterase inhibitors have
demonstrated the importance of cAMP in the protection against
lung and liver damage in sepsis, as well as protection of cardiac
function, normalization of urinary volume, improved systemic
vasoconstriction, reduced plasma leakage and decreased
chemical markers of endotoxic shock [7,8,31–38]. As we
aimed to study the potential regulation of adenylyl cyclases that
may play important roles in inflammatory mediator release, we
also isolated and examined two major macrophage populations
from liver and lung. Macrophages are key players in the balance
of host defences, secreting mediators which activate and
coordinate further immune responses. A notable finding was
the considerably higher levels of AC7 and AC9 mRNA in both
bronchoalveolar macrophages and Kupffer cells compared to
observed levels in their respective surrounding tissues. The
presence of sAC mRNA in both populations was also
demonstrated for the first time.
When examining mRNA expression of adenylyl cyclase
isoforms in our animal endotoxemia model, we revealed a
previously uncharacterized, marked downregulation of many
isoforms after 6 h of LPS treatment. The rats in this model
develop multiple organ damage within that period of time,
assessed both morphologically and by markers of liver and
kidney injury [39]. We found that AC5, AC6, AC7 and AC9
were downregulated to some degree in most tissues as well as in
resident macrophages. An inhibition of adenylyl cyclase
expression would be in agreement with several studies reporting
reductions in cAMP levels in liver, heart and spleen during
sepsis in animal models [40–45].
As the promotors of adenylyl cyclase isoforms have only
been scarcely studied, the molecular basis for modulation of
adenylyl cyclase mRNA levels by lipopolysaccharide remains
speculative. However, it seems reasonable to assume that the
reduced ACmRNA expression will lead to a decreased potentialfor cAMP production. Other mechanisms of LPS-mediated
reduction of cAMP production have been proposed previously.
A mechanism of adenylyl cyclase inhibition by HSP90, a
member of the receptor complex associated with TLR-4, has
been proposed [29], and LPS is also demonstrated to increase
phosphodiesterase activity, leading to rapid inactivation of the
cAMP signal [46]. We suggest that reduced AC expression is
another important mechanism by which LPS may impair normal
cAMP production.
An increased understanding of the cAMP pathway response
to sepsis is probably fundamental to understanding the signaling
deficiencies present during septic shock and how cAMP-
inducing agents exert their therapeutic effects. However, present
knowledge about the functional importance of particular
adenylyl cyclase isoforms in inflammation and sepsis is limited.
Establishing the biological importance of AC isoforms calls for
isoform-specific inhibitors, but there are currently only
developed partly specific inhibitors for AC5 and sAC [47,48].
Adenylyl cyclase isoforms highly expressed in heart, AC5
and AC6, probably have the best established functions.
Transgenic mice over-expressing AC6 have a normal heart
function under basal conditions, an augmented cardiac respon-
siveness to stress, i.e. adrenergic stimulation, and increased
survival in cardiomyopathy [49–52]. In contrast, disruption of
AC5 in mice has been demonstrated to preserve cardiac func-
tion against pressure overload and protect against myocardial
apoptosis [53]. The results from the transgenic studies would
suggest that down-regulation of AC6 in favor of AC5 may lead
to lowered responsiveness to adrenergic stimulation and/or
enhanced myocardial apoptosis leading to heart failure, clearly
correlating with the common observations and clinical problems
in septic shock. We found a highly significant 70% reduction of
AC6 mRNA production in heart after 6 h of endotoxemia with
no significant reduction in AC5 mRNA, an observation that
may be potentially very interesting in this context. AC6 is also
reported to be directly implicated in the inhibition of thrombin-
induced endothelial cell gap formation, causing a rise in cAMP
which strongly attenuates plasma leakage [54]. Interestingly,
cytosolic cAMP produced by sAC was demonstrated to have
the opposite effect [55]. Plasma leakage due to a failing
endothelial barrier function is a commonly observed complica-
tion in sepsis, and that AC6 mRNA levels are reduced in
endotoxemic heart, kidney and spleen may possibly influence
endothelial barrier function.
AC9 mRNA levels were most consistently inhibited by LPS
in all tissues examined in our study, and was one of the
dominating AC isoform mRNAs in tissue macrophages. We
have previously reported that forskolin insensitive AC9 may
serve a role in cAMP-mediated inhibition of TNFα production
in Kupffer cells, due to divergent effects of forskolin [16]. Our
analysis of cAMP levels in Kupffer cells demonstrated that LPS
treatment for 6 h abolished PGE2-mediated cAMP production
although forskolin-mediated cAMP production was unaltered.
This is also shown in murine macrophages [46]. Although it
may not be ruled out that these results are due to inhibition of
other players in PGE2 signaling, they may indicate a role of
AC9 in PGE2-mediated cAMP production. This is interesting in
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inhibitor of TNFα production in Kupffer cells compared to
forskolin, and that this effect is lost following prolonged LPS
pretreatment [16]. Another study indicating a possible function
of AC9 in immunity is a clinical study in 436 asthmatic children
that reported a highly significant interaction between an AC9
polymorphism and an enhanced cAMP-response during
corticosteroid treatment [56]. This may imply that AC9
polymorphisms exist that could alter individual responses to
treatment also in sepsis.
In contrast to the other adenylyl cyclases, AC4 mRNA
exhibited a 4- to 5-fold increase in heart and lung, whereas it was
virtually abolished in spleen and demonstrated relatively little
change in other tissues or in resident macrophages. It should be
noted that the primers used amplified a product corresponding to
a shorter AC4 splice variant lacking exon 2. While considerable
elevation of AC4 mRNA by LPS treatment is interesting, it is at
present unknown whether the changes are due to redistribution
of circulating immune cells, or to differential regulation of
mRNA production. Rapid leukocyte recruitment to lung has
been demonstrated in the rat endotoxemia model [8], and may
support a redistribution hypothesis if leukocytes are rich in AC4
mRNA. There may also be a link to the total depletion of AC4
mRNA expression observed in spleen. Sepsis is shown to
induce macrophage apoptosis in spleen [57], a phenomenon
that may explain the particular attenuation of AC4, AC7 and
AC9 mRNAs that are highly expressed in macrophages.
In conclusion, adenylyl cyclase mRNA levels are reduced in
endotoxemic animals, partly due to the effects of LPS on
expression in tissue macrophages. In light of the undisputable
importance of cAMP signaling in many of the physiological
functions impaired in sepsis, our data may provide important
new information to increase the understanding of sepsis
pathophysiology. As future research provide us with tools for
specific targeting of individual AC isoforms, their physiological
roles and potential as targets for intervention in sepsis can be
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